Is it Possible to Accurately Evaluate the Tumor Bed After Neoadjuvant Chemotherapy Using a 14-G Tru-cut Biopsy?
Preprint
- 10 February 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Background/Objectives: Accurately detecting residual disease and potentially omitting surgery is crucial in breast cancer treatment. However, no reliable method confirms pathologic complete response (pCR) after neoadjuvant systemic therapy (NST). This study evaluates the reliability of ultrasound-guided 14G trucut biopsy in assessing post-NST disease status. Methods: Data from 204 breast cancer patients who underwent ultrasound-guided 14G trucut biopsy before surgery at Istanbul University Oncology Institute (March 2015–May 2024) were analyzed. Concordance between trucut biopsy and final pathology was assessed, along with diagnostic accuracy parameters, including false-negative rate (FNR), accuracy, negative predictive value (NPV), and positive predictive value (PPV). Results: The median patient age was 45 years (range: 26–86). The median initial tumor size was 32 mm, reducing to 10 mm post-treatment. Pathologic complete response (pCR) was 33.8% in surgical specimens and 40.7% in biopsy samples. Biopsy misdiagnosed 15 patients, with an overall FNR of 11.1% and accuracy of 92.2% (95% CI, 7.1–18.1%; 95% CI, 87.6–95.5%). Among patients with radiologic complete response (rCR) (n = 99), FNR was 25.8%, and accuracy was 92.1%. The best outcomes were in the rCR and trucut pCR subgroup, with an FNR of 5.9% and accuracy of 95.6%. In triple-negative breast cancer patients, FNR was 5%, and accuracy was 97.4%. Conclusions: Although obtaining eight or more samples with a 14G tru-cut biopsy after NST is insufficient to alter clinical practice for detecting residual disease, the promising results observed in the rCR and tru-cut pCR subgroups suggest its potential role in guiding treatment strategies.Keywords
All Related Versions
This publication has 27 references indexed in Scilit:
- Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast CancerJAMA Oncology, 2021
- Accuracy of Post–Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual CancerJAMA Surgery, 2020
- Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trialBreast Cancer Research and Treatment, 2020
- Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trialThe Lancet Oncology, 2018
- Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?European Journal of Cancer, 2016
- Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniquesBritish Journal of Cancer, 2015
- Meta-Analysis of Magnetic Resonance Imaging in Detecting Residual Breast Cancer After Neoadjuvant TherapyJNCI: Journal of the National Cancer Institute, 2013
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Imaging in Evaluation of Response to Neoadjuvant Breast Cancer Treatment Benefits of MRIBreast Cancer Research and Treatment, 2002
- Mammography in the assessment of response to medical treatment of large primary breast cancerClinical Radiology, 1993